Clinical Trial Update: Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating nivolumab alone or with ipilimumab in unresectable malignant pleural mesothelioma has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Intergroupe Francophone de Cancerologie Thoracique | Conditions: Mesothelioma | Phase 2 | Status: COMPLETED